Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO plus IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC)

被引：2
|
作者：
Lemelin, A. [1 ]
Takemura, K. [2 ]
Boyne, D. J. [3 ]
Warkentin, M. T. [3 ]
Brenner, D. R. [3 ]
Cheun, W. Y. [3 ,6 ]
Wells, J. C. [4 ]
Labaki, C.
McGregor, B. A. [6 ]
Basappa, N. S. [7 ]
Meza, L. A. [8 ]
Pal, S. K. [8 ]
Beuselinck, B. [9 ]
Mckay, R. R. [10 ]
Szabados, B. E. [11 ]
Powles, T. B. [12 ]
Yuasa, T. [13 ]
Ludwig, L. [14 ]
Choueiri, T. K. [5 ]
Heng, D. Y. C. [2 ]
机构：
[1] Tom Baker Canc Clin, Med Oncol, Calgary, AB, Canada
[2] Tom Baker Canc Clin, Oncol Dept, Calgary, AB, Canada
[3] Univ Calgary, Oncol Dept, Oncol, Calgary, AB, Canada
[4] BC Canc Agcy, Oncol, Vancouver, BC, Canada
[5] Dana Farber Canc Inst, Med Genet Unit, Boston, MA USA
[6] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[7] Cross Canc Inst, Med Oncol Dept, Edmonton, AB, Canada
[8] City Hope Comprehens Canc Ctr, Med Oncol, Duarte, CA USA
[9] Univ Hosp Leuven, Dept Gen Med Oncol, Campus Gasthuisberg, Leuven, Belgium
[10] Univ Calif San Diego, Oncol, Moores Canc Ctr, La Jolla, CA USA
[11] Barts & London Queen Marys Sch Med & Dent, Med Oncol Dept, Canc Res UK Barts Ctr, London, England
[12] Queen Mary Univ London, Barts Canc Inst, St Bartholomews Hosp, Expt Canc Med Ctr, London, England
[13] JFCR, Urol, Canc Inst Hosp, Koto Ku, Tokyo, Japan
[14] Ipsen Biopharmaceut Canada Inc, Med Sci Liaison, Mississauga, ON, Canada
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1132
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1902P
引用
收藏
页码：S1023 / S1024
页数：2
相关论文
共 50 条
  • [21] Ipilimumab and nivolumab (I plus N) as first-line treatment of metastatic renal cell carcinoma (mRCC): A real-world review in North West of England, United Kingdom.
    Allison, Jennifer
    Griffiths, Richard
    Waddell, Tom
    Pillai, Manon Rhys
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [22] Nivolumab (NIVO) plus chemotherapy (chemo) or NIVO plus ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): first report of the CheckMate 648 study
    Greil, R.
    Chau, I
    Doki, Y.
    Ajani, J. A.
    Xu, J.
    Wyrwicz, L.
    Motoyama, S.
    Ogata, T.
    Kawakami, H.
    Hsu, C. -H
    Adenis, A.
    el Hajbi, F.
    Di Bartolomeo, M.
    Braghiroli, Ignez M.
    Holtved, E.
    Xynos, I
    Liu, X.
    Lei, M.
    Kondo, K.
    Kato, K.
    Kitagawa, Y.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 81 - 82
  • [23] Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.
    Chau, Ian
    Doki, Yuichiro
    Ajani, Jaffer A.
    Xu, Jianming
    Wyrwicz, Lucjan
    Motoyama, Satoru
    Ogata, Takashi
    Kawakami, Hisato
    Hsu, Chih-Hung
    Adenis, Antoine
    El Hajbi, Farid
    Di Bartolomeo, Maria
    Freitas Melro Braghiroli, Maria Ignez
    Holtved, Eva
    Xynos, Ioannis
    Liu, Xuan
    Lei, Ming
    Kondo, Kaoru
    Kato, Ken
    Kitagawa, Yuko
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (18)
  • [24] Nivolumab plus ipilimumab (NIVO plus IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial
    Escudier, Bernard
    Mcdermott, David F.
    Burotto, Mauricio
    Choueiri, Toni K.
    Hammers, Hans J.
    Plimack, Elizabeth R.
    Porta, Camillo
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Atkins, Michael B.
    Kollmannsberger, Christian K.
    Grimm, Marc-Oliver
    Tomita, Yoshihiko
    Rini, Brian I.
    Jiang, Ruiyun
    Desilva, Heshani
    Lee, Chung-Wei
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 363 - 363
  • [25] Real-world assessment of changing treatment patterns and sequence for patients with metastatic renal cell carcinoma (mRCC) in the first-line (1L) setting.
    Shah, Neil J.
    Sura, Sneha
    Shinde, Reshma
    Shi, Junxin
    Perini, Rodolfo F.
    Puneet, Singhal
    Robert, Nicholas J.
    Vogelzang, Nicholas J.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [26] Interim data of effectiveness and safety of nivolumab plus ipilimumab combination therapy (NIVO plus IPI) in first line (1L) advanced/metastatic renal cell carcinoma (aRCC) from the German non-interventional study (NIS) NORA
    Bedke, Jens
    Mueller-Huesmann, Harald
    Belz, Hanjo
    von der Heyde, Eyck
    Boegemann, Martin
    Strauss, Arne
    Ivanyi, Philipp
    Wiegand, Jörg
    Autengruber, Andrea
    Grimm, Marc-Oliver
    Gruenwald, Viktor
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 103 - 104
  • [27] Comparative effectiveness of first-line (1L) ipilimumab plus nivolumab (Ipi plus Nivo) versus immune checkpoint inhibitors plus tyrosine kinase inhibitors (ICI plus TKI) in patients (pts) with intermediate or poor (I/P) risk metastatic clear cell renal cell carcinoma (mccRCC)
    Ostrowski, Micah
    Jo, Yeonjung
    Gebrael, Georges
    Chehade, Chadi Hage
    Narang, Arshit
    Fortuna, Gliceida Galarza
    Thomas, Vinay Mathew
    Chigarira, Beverly
    Anderson, Ethan
    Mazumder, Archisman
    Ozay, Zeynep Irem
    Agarwal, Neeraj
    Maughan, Benjamin L.
    Swami, Umang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] Comparative effectiveness of second-line (2L) treatment (Rx) with cabozantinib (cabo) in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) after first-line (1L) Rx with ipilimumab plus nivolumab (ipi plus nivo) vs. PD-1/L1 inhibitor (PDI) plus tyrosine kinase inhibitor (TKI)
    Gebrael, G.
    Jo, Y. Jung
    Thomas, V. Mathew
    Li, H.
    Fortuna, G. Galarza
    Sahu, K.
    Sayegh, N.
    Tripathi, N.
    Chigarira, B.
    Srivastava, A.
    Chehade, C. Hage
    Nordblad, B.
    Dal, E.
    Brundage, J.
    Maughan, B. L.
    Agarwal, N.
    Swami, U.
    ANNALS OF ONCOLOGY, 2023, 34 : S1022 - S1022
  • [29] Impact of smoking status (SS) on the clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first line (1L) immuno-oncology (IO)-combination regimens: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
    Gebrael, Georges
    Saad, Eddy
    Labaki, Chris
    Saliby, Renee Maria
    Sayegh, Nicolas
    Wells, J. Connor
    Semaan, Karl
    Eid, Marc
    Takemura, Kosuke
    Ernst, Matthew Scott
    Lemelin, Audreylie
    Basappa, Naveen S.
    Wood, Lori
    Powles, Thomas
    Ernst, D. Scott
    Kapoor, Anil
    Xie, Wanling
    Agarwal, Neeraj
    Heng, Daniel Yick Chin
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] Comparison of Cabozantinib and Axitinib as Second-line Therapy After Nivolumab Plus Ipilimumab in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Comparative Analysis of Retrospective Real-world Data
    Tomida, Ryotaro
    Takahashi, Masayuki
    Matsushita, Yuto
    Kojima, Takahiro
    Yamana, Kazutoshi
    Kandori, Shuya
    Bando, Yukari
    Nishiyama, Naotaka
    Yamashita, Shimpei
    Taniguchi, Hisanori
    Monji, Keisuke
    Ishiyama, Ryo
    Tatarano, Shuichi
    Masui, Kimihiko
    Matsuda, Ayumu
    Kaneko, Tomoyuki
    Motoshima, Takanobu
    Shiraishi, Yusuke
    Kira, Satoru
    Murashima, Takaya
    Hara, Hiroaki
    Matsumura, Masafumi
    Kitamura, Hiroshi
    Miyake, Hideaki
    Furukawa, Junya
    CLINICAL GENITOURINARY CANCER, 2024, 22 (03)
12345